All 1 tracked stories fall under one category: medical-devices. Charles Schwab is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 3.3 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about SecurDx
All 1 tracked stories fall under one category: medical-devices. Charles Schwab is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 3.3 across the same-window beat baseline. At 7, the average consequence score sits above the same-window beat average of 6.6. We currently track 1 Healthcare story that mention SecurDx, all published on March 25, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering SecurDx. Shared-story counts are live from our verified record — not editorial picks.
MaxCyte reported a 15% revenue decline for 2025, driven by the loss of six clinical programs and reduced spending from its largest customer. Despite these headwinds, the company expanded its installed base to 857 units and significantly improved gross margins through aggressive cost-cutting measures.